Home > Result Summaries: Compounds > ondansetron > Result Summary for S3AA3012

Result Summary for S3AA3012

Result Summary

Protocol ID:	S3AA3012
Clinical Study ID:	S3AA3012
Official Title:	A Randomized, Double-Blind Study of Oral Ondansetron, 8mg Twice Daily, 24mg Once Daily and 32mg Once Daily, in the Prevention of Nausea and Vomiting Associated With Cisplatin Chemotherapy
Phase:	Phase 3
Study Indications or Diseases:	Nausea and Vomiting, Chemotherapy-Induced
Generic Name:	ondansetron
Trade/Product Name:	zofran;zofran
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Needles B, Miranda E, Garcia Rodriguez FM, Diaz LB, et al. A multicenter, double-blind, randomized comparison of oral ondansetron 8mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with highly emetogenic chemotherapy. Supportive Care in Cancer 1999;7(5):347-353.